Drug interaction between St John's Wort and quazepam
Open Access
- 27 July 2004
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 58 (4) , 403-410
- https://doi.org/10.1111/j.1365-2125.2004.02171.x
Abstract
Aim: St John's Wort (SJW) enhances CYP3A4 activity and decreases blood concentrations of CYP3A4 substrates. In this study, the effects of SJW on a benzodiazepine hypnotic, quazepam, which is metabolized by CYP3A4, were examined.Methods: Thirteen healthy subjects took a single dose of quazepam 15 mg after treatment with SJW (900 mg day−1) or placebo for 14 days. The study was performed in a randomized, placebo‐controlled, cross‐over design with an interval of 4 weeks between the two treatments. Blood samples were obtained during a 48 h period and urine was collected for 24 h after each dose of quazepam. Pharmacodynamic effects were determined using visual analogue scales (VAS) and the digit symbol substitution test (DSST) on days 13 and 14.Results: SJW decreased the plasma quazepam concentration. The Cmax and AUC0‐48 of quazepam after SJW were significantly lower than those after placebo [Cmax; −8.7 ng ml−1 (95% confidence interval (CI) −17.1 to −0.2), AUC0‐48; −55 ng h ml−1 (95% CI −96 to −15)]. The urinary ratio of 6β‐hydroxycortisol to cortisol, which reflects CYP3A4 activity, also increased after dosing with SJW (ratio; 2.1 (95%CI 0.85–3.4)). Quazepam, but not SJW, produced sedative‐like effects in the VAS test (drowsiness; P < 0.01, mental slowness; P < 0.01, calmness; P < 0.05, discontentment; P < 0.01). On the other hand, SJW, but not quazepam impaired psychomotor performance in the DSST test. SJW did not influence the pharmacodynamic profile of quazepam.Conclusions: These results suggest that SJW decreases plasma quazepam concentrations, probably by enhancing CYP3A4 activity, but does not influence the pharmacodynamic effects of the drug.Keywords
This publication has 38 references indexed in Scilit:
- St John's wort (Hypericum perforatum): drug interactions and clinical outcomesBritish Journal of Clinical Pharmacology, 2002
- The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy menBritish Journal of Clinical Pharmacology, 2002
- St John's Wort increases expression of P‐glycoprotein: Implications for drug interactionsBritish Journal of Clinical Pharmacology, 2002
- The Gut as a Barrier to Drug AbsorptionClinical Pharmacokinetics, 2001
- Cytochrome P450 3AClinical Pharmacokinetics, 1999
- Genetic analysis of CYP2C9 polymorphism in a Japanese populationPharmacogenetics, 1997
- Quantitation of cortisol and related 3-oxo-4-ene steroids in urine using gas chromatography/mass spectrometry with stable isotope-labeled internal standardsSteroids, 1996
- P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.Journal of Clinical Investigation, 1996
- Benzodiazepine receptor binding of benzodiazepine hypnotics: Receptor and ligand specificityPharmacology Biochemistry and Behavior, 1992
- Influence of different paths on spatial memory performance in the block-tapping testJournal of Clinical Neuropsychology, 1983